South Africa is making history as local patients take part in a pioneering global clinical trial using CRISPR-Cas9 gene-editing technology to treat hereditary angioedema (HAE)—a rare and potentially fatal genetic condition. Led by Professor Jonny Peter at UCT’s Lung Institute, the trial could offer a one-time curative therapy by targeting the root cause of the disease.

Read the full article here: UCT Lung Institute joins global CRISPR trial for hereditary angioedema

Reference:
Peter J et al. (2023). A Randomized Trial of CRISPR-Cas9 In Vivo Gene Editing for Hereditary Angioedema. New England Journal of Medicine.